RxDoctor Payments Data

Lyn Hopkinson, NP

Acute Care · Washington, DCNPI 1013962471

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 94.8% of the total across 12 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 7 manufacturers reported payments, led by Abbott at 30.4% of the total. Reporting peaked in 2021 at $91 and has fallen 61.4% since, to $35 in 2025.

$226in general payments, 2019–2025

Across 12 payments — averaging $18.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$69
  • Dexcom, Inc.$51
  • Caris MPI, Inc.$35
  • E.r. Squibb & Sons, L.L.C.$21
  • Medtronic$21
  • Insulet Corporation$18
  • plus $12 from 1 others

What the payments were for

  • Food & beverage$21495%
  • Education$125%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$226 in reported general payments places this provider in the 60th percentile of 110 acute care providers in District of Columbia.

See all acute care providers in District of Columbia

Medicare billing

Part B allowed, 2024
$47,595
Medicare patients
172
Services billed
373

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide140$162,799
JardianceEmpagliflozin100$102,655
TrulicityDulaglutide86$97,571
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/758$74,494
OzempicSemaglutide34$62,611
JanuviaSitagliptin Phosphate31$39,585
Omnipod Dash Pods (Gen 4)Insulin Pump Cart,cont Inf,bt15$21,208
Tresiba Flextouch U-100Insulin Degludec34$20,041
Lantus SolostarInsulin Glargine,hum.Rec.Anlog105$14,410
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog34$14,274
Tresiba Flextouch U-200Insulin Degludec18$13,794
Fiasp FlextouchInsulin Aspart (Niacinamide)17$11,861
Nano 2nd Gen Pen NeedlePen Needle, Diabetic116$10,971
Humalog Kwikpen U-100Insulin Lispro44$10,048
Insulin Lispro Kwikpen U-100Insulin Lispro38$9,631

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro$12$268,066278 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 110 acute care providers in District of Columbia.

Other acute care in Washington

See the full list for District of Columbia

Where these figures come from

Is this you, or does something look wrong? →